Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-09 14:00 |
Xbrane Biopharma AB (publ) (“Xbrane” eller “bolaget) utser Jane Benyamin till t…
|
Swedish | 60.1 KB | ||
| 2025-01-09 14:00 |
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as…
|
English | 58.6 KB | ||
| 2024-12-31 09:00 |
XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
|
English | 68.6 KB | ||
| 2024-12-31 09:00 |
XBRANE LÄMNAR in BLA FÖR RANIBIZUMAB BIOSIMILAR KANDIDAT TILL FDA
|
Swedish | 68.8 KB | ||
| 2024-12-18 14:40 |
Xbrane announces outcome of exercise of warrants of series TO1
|
English | 62.3 KB | ||
| 2024-12-18 14:40 |
Xbrane offentliggör utfall av utnyttjande av teckningsoptioner av serie TO1
|
Swedish | 62.2 KB | ||
| 2024-12-02 14:30 |
XBRANE BIOPHARMAS HUVUDÄGARE SYSTEMATIC GROUP GER KORTSIKTIGT LÅN PÅ 20 MSEK TI…
|
Swedish | 67.3 KB | ||
| 2024-12-02 14:30 |
XBRANE BIOPHARMA'S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN …
|
English | 67.3 KB | ||
| 2024-11-26 17:20 |
Xbrane AB (publ) informerar idag att bolagets CFO, Anette Lindqvist, har meddel…
|
Swedish | 69.2 KB | ||
| 2024-11-26 17:20 |
Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has …
|
English | 69.0 KB | ||
| 2024-11-21 08:00 |
XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES
|
English | 61.5 KB | ||
| 2024-11-21 08:00 |
XBRANE BIOPHARMA MEDDELAR FÖRÄNDRING AV VALBEREDNING
|
Swedish | 60.9 KB | ||
| 2024-11-19 12:20 |
Xbrane och Intas ingår ett globalt licens- och samutvecklingsavtal för Xbranes …
|
Swedish | 78.9 KB | ||
| 2024-11-19 12:20 |
Xbrane and Intas enter into a Global Licensing agreement to jointly develop Niv…
|
English | 79.0 KB | ||
| 2024-10-31 14:35 |
XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE
|
English | 61.4 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
